Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
Marc Humbert(Inserm), K. Surrey(Novartis (United Kingdom)), S. Hedgecock(Novartis (United Kingdom)), Martin Blogg(Novartis (United Kingdom)), Jean‐Louis Hébert(Centre hospitalier de l'Université Laval), Richard Beasley(Medical Research Institute of New Zealand), Sância Ramos(Hospital Universitario Central de Asturias), Jean Bousquet(Charité - Universitätsmedizin Berlin), H. Fox, Jon G. Ayres(Forest Research), Raymond G. Slavin(Saint Louis University), K.M. Beeh(Johannes Gutenberg University Mainz), Giorgio Walter Canonica(Humanitas University)
Cited by 1,117
Related Papers
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.4k
Pathologic assessment of vasculopathies in pulmonary hypertension
|Journal of the American College of Cardiology|2004|713